Fumi Higuchi

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

Hideyuki Arita, Kai Yamasaki, Yuko Matsushita et al. · Acta Neuropathologica Communications · 2016 · 257 citations · Full text

Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma

Christian Braun, Monica Stanciu, Paul L. Boutz et al. · Cancer Cell · 2017 · 218 citations · Full text

Transcriptional Regulation, Glioma, Medicine +11

Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair

Fumi Higuchi, Hiroaki Nagashima, Jianfang Ning et al. · Clinical Cancer Research · 2020 · 110 citations

TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma

Kenji Fujimoto, Hideyuki Arita, Kaishi Satomi et al. · Acta Neuropathologica · 2021 · 103 citations

Neuro-oncology, Somatic Variant, Medicine +9

The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i> -Mutant Cancers and Potentiates NAD+ Depletion–Mediated Cytotoxicity

Kensuke Tateishi, Fumi Higuchi, Julie J. Miller et al. · Cancer Research · 2017 · 92 citations · Full text